

IV to PO Step-Down Criteria

Many clinical trials support switching to PO antibiotics after **two to three days** of IV therapy.

When switching is APPROPRIATE

- Absence of suppurative infection or positive blood cultures
- Ability to maintain oral intake or access to functional NG tube
- Temperature less than or equal to 38 °C for at least 24h
- Patient is stable (baseline respiratory rate, WBC less than $11 \times 10^9/L$)
- For the **following conditions**:
 - Hospital-acquired infections
 - Intra-abdominal infections
 - Pneumonia
 - Skin and soft tissue infections
 - Urinary tract infections

When switching is NOT APPROPRIATE

- Infection requiring very high plasma concentrations or extended IV therapy (e.g. meningitis, endocarditis, bone/joint infections, deep-seated abscess/empyema)
- Patient is immunocompromised (e.g. neutropenia or HIV)
- Patient is NPO or has GI dysfunction
- Patient has condition or drug interaction that can affect bioavailability of oral agent
- Patient is in the ICU

IV to PO Step-Down Chart

| Usual IV Dose | Usual PO Dose | PO Bioavailability | ORAL Renal Dose Adjustments |
|--|---|----------------------------------|--|
| acyclovir 5 to 10 mg/kg Q8H | valACYclovir 1 gram Q8H | ~55% once converted to acyclovir | CrCl greater than 30 mL/min: no dosage adjustment CrCl 15 to 30 mL/min: 1 gram Q12H CrCl less than 15 mL/min : 1 gram Q24H |
| ampicillin 1 to 2 grams Q6H | amoxicillin 250 to 500 mg Q8H | 100% | CrCl 10-30 mL/min: 250-500 mg Q12H CrCl less than 10 mL/min: 250-500 mg Q24H |
| azithromycin 500 mg Q24H | azithromycin 250-500 mg Q24H | 38% | None |
| ceFAZolin 1 to 2 grams Q8H | cephalexin 250 to 500 mg Q6H | 90% | CrCl 10-50 mL/min : 500 mg Q8-12H CrCl less than 10 mL/min : 250 to 500 mg Q12-24H |
| cloxacillin 1 to 2 grams Q4-6H | cloxacillin 250 to 500 mg Q6H | 90% | None |
| cefTRIAxone 1 to 2 grams Q24H | amoxicillin/clavulanate 250/125 to 500/125 mg Q8H | 100% | CrCl 10 to 30 mL/min: 250 to 500 mg Q12H CrCl less than 10 mL/min: 250 to 500 mg Q24H |
| cefOXitin 1 to 2 grams Q6-8H | cephalexin 500 mg Q6H & metroNIDAZOLE 500 mg Q8H | | CrCl 10-50 mL/min : 500 mg Q8-12H CrCl less than 10 mL/min : 250 to 500 mg Q12-24H |
| ceftazidime 1 to 2 grams Q8H | ciprofloxacin 250 to 750 mg Q12H | ~70% | CrCl 30 to 50 mL/min : 250 to 500 mg Q12H CrCl 5 to 30 mL/min : 250 to 500 mg Q24H |
| cefuroxime 0.75 to 1.5 grams Q8H | cefuroxime axetil 500 mg Q12H | | CrCl 10 to 30 mL/min : 500 mg Q24H CrCl less than 10 mL/min : 500 mg Q48H |
| ciprofloxacin 200 to 400 mg Q12H | ciprofloxacin 250-750 mg Q12H | ~70% | CrCl 30 to 50 mL/min : 250 to 500 mg Q12H CrCl 5 to 30 mL/min : 250 to 500 mg Q24H |
| clindamycin 600 mg Q8H | clindamycin 300 mg Q6H | 90% | None |
| co-trimoxazole 10 to 20 mg/kg/day TMP divided Q6-8H | co-trimoxazole DS (double strength) Q12H | | CrCl 15 to 30 mL/min : SS (single strength) Q12H CrCl less than 15 mL/min : not recommended |
| fluconazole 100 to 400 mg Q24H | fluconazole 100 to 400 mg Q24H | >90% | CrCl less than 50 mL/min: 50% of dose Q24H |
| levofloxacin 500-750 mg Q24H | levofloxacin 500-750 mg Q24H | 99% | (for 750 mg Q24H dose) CrCl 20-49 mL/min: 750 mg Q48H CrCl 10-19 mL/min: 750 mg once, then 500 mg Q48H |
| linezolid 600 mg Q12H | linezolid 400-600 mg Q12H | 100% | None |
| metroNIDAZOLE 500 mg Q8H | metroNIDAZOLE 500 mg Q8H | 100% | None |
| penicillin G 1 to 2 million units Q4-6H | penicillin V 300 mg QID | | None |
| piperacillin-tazobactam 3.375 grams Q6H | amoxicillin-clavulanate 250/125 to 500/125 mg Q8H | | CrCl 10 to 30 mL/min: 250 to 500 mg Q12H CrCl less than 10 mL/min: 250 to 500 mg Q24H |

*Once sensitivity is known, selection of oral agent should be based on resistance/sensitivity data